Symposium Details

A number of risk factors, cholesterol is key one, contribute to the development and progression if CVD. Recent evidence confirms that exposure over time, years, to even mildly or moderately elevated levels of i.ve. LDL-C determines the risk of future cardiovascular event. At the last ESC, an algorithm has been presented estimating the CV risk based on exposure of a specific levels of LDL-C over several years.

Early population strategies aimed at lowering LDL-C based on lifestyle and the use in specific cases of nutraceuticals, such as RYR, leading to a moderated LDL-C reduction, if maintained over time will result in significant, remarkable reduction in CV event of these individuals 10-20 years later in their lives a should be implemented by health care systems to reduce CVD risk in large number of individuals.

Although LDL remains the therapeutic #1 target we nowadays have a clear, robust evidence that TG-rich lipoproteins containing Apo B and particularly their remnants are equally atherogenic on a per-particle basis as LDL. These lipoproteins significantly impact on the residual risk of further CV events in patients i.e. with central obesity and type II diabetes even at LDL-C extremely low i.e. < 1 mmol/L.

As it is already suggested by the most recent guidelines of Hypertension and Diabetes, I believe that long-term treatment (with of course an adequate therapeutic adherence) of combinations of LDL and TG-rich lipoprotein lowering agents targeting all the Apo B containing lipoproteins is the paved road for the most effective reduction of CVD morbidity and mortality.